Iso Endoxan is a pharmaceutical drug that falls under the category of alkylating agents, specifically belonging to the class of nitrogen mustard compounds. Also known by its generic name Isophosphamide, Iso Endoxan is a derivative of the cytotoxic drug Cyclophosphamide, but with a modified structure. It is commonly used in the treatment of various types of cancers, such as lymphomas, multiple myeloma, breast cancer, as well as solid tumors affecting the lungs, ovaries, bladder, and testicles.
Iso Endoxan works by inhibiting the growth and multiplication of cancer cells in the body. It does so by interfering with the DNA repair processes and crosslinking DNA strands, leading to the disruption of cellular replication and ultimately causing cell death. This drug is typically administered in the form of intravenous infusion or injection.
As with any medication, Iso Endoxan may have potential side effects. Commonly reported adverse reactions include gastrointestinal disturbances like nausea and vomiting, myelosuppression resulting in lowered blood cell counts (anemia, leukopenia, thrombocytopenia), increased susceptibility to infections, hair loss, hemorrhagic cystitis, and mild to moderate renal toxicity. Additionally, it is crucial to note that Iso Endoxan can cause infertility and may have teratogenic effects if used during pregnancy.
Due to its potent anticancer properties and relatively broad spectrum of activity against different types of tumors, Iso Endoxan has become an important chemotherapeutic option for many cancer patients. However, its usage must be closely monitored by healthcare professionals, who will tailor the dosage and treatment duration according to individual patient characteristics and cancer stage.
